News12 Feb 2024 18:36
Nano-cap HealthTech Renalytix (NASDAQ:RNLX) surged more than 500% on Monday after the company announced a draft Medicare policy that, if finalized, will establish coverage for its diagnostic platform, KidneyIntelX, and its testing service, KidneyIntelX.dkd.
The so-called Local Coverage Determination (βLCDβ) has indicated pricing for KidneyIntelX and kidneyintelX at $950 per test, according to the New York-based company.